ON101 is a novel, non-invasive option for hematologic–metabolic overlap wounds. In a PV patient with a hydroxyurea-induced ulcer showing no significant healing for over 5 months, ON101 treatment achieved:
This case supports ON101 as a valuable therapeutic adjunct for refractory ulcer populations—especially for patients who aren’t surgical candidates or have failed standard of care (SOC).
ON101 enabled fast and complete healing of a chronic PV/DM-associated heel ulcer, resolving a previously intractable case. This outcome reinforces ON101’s utility in non-DFU wound etiologies, warranting broader evaluation in patients with hematologic and metabolic comorbidities.
Polycythemia Vera (PV) is a myeloproliferative neoplasm often treated with hydroxyurea. However, hydroxyurea-induced chronic leg ulcers are a rare but significant adverse event. When coupled with type 2 diabetes mellitus (DM), wound healing is further compromised by microvascular dysfunction and poor tissue regeneration. We report a case of a chronic heel ulcer unresponsive to conventional therapy, which achieved rapid healing with ON101 topical macrophage-modulating cream.